The Healthscope Ltd (ASX: HSO) share price is up by 6% thanks to an update surrounding the potential takeover bid.

Healthscope is the second largest private hospital business in Australia, it employs over 18,000 staff. The business was formed in 1985 and re-listed onto the ASX in July 2014 after a period of private equity ownership.

Why Healthscope shares are up 6%

Healthscope provided an update to the market to say that potential takeover suitor Brookfield has done a substantial amount of its due diligence and at this stage has no reason why it won’t continue with the takeover through a scheme of arrangement for a value of $2.585 per share.

But, it isn’t yet a done deal. Brookfield still needs to complete its due diligence and arrange committed debt financing. To make sure this can happen, Healthscope and Brookfield have agreed to extend the exclusivity to 5pm on 18 January 2019.

Is it worth buying Healthscope shares?

Healthscope shares are currently trading at $2.19, so it does suggest a potential gain of 18%, or a 11% gain to the separate off-market takeover offer of $2.455 per share.

The takeover is not guaranteed so investors would be taking a risk with a limited upside at this stage. It might be a wiser move to go for shares not going through a takeover with a proven track record, such as the shares in the free report below.


After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.

Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 300.

Idea #1 is taking on the world with an online marketplace capable of generating serious free cash flow. This company's addressable opportunity is multiples of its current valuation.

Idea #2 is a technology business with super-sticky revenue and mission critical software. With operations around the globe, this growth stock has many years of potential.

Access the free report by clicking here now. Absolutely no credit card or payment details required.

Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).